Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Top Managements of Pharmaceutical Companies Express Complaints for Additional Price Cut for Long-Listed Drugs
January 10, 2012
- Bayer Yakuhin to Promote Long-Listed Products Without Mediation by MRs
January 10, 2012
- Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
- Toho HD Chairman Matsutani Showed Enthusiasm for 3rd Round of Distribution Improvement Talks
January 10, 2012
- Takeda and Osaka Univ. Establish Joint Research Chair for Nano-particle Vaccines
January 10, 2012
- Astellas Terminates License Agreement for VIBATIV Injection
January 10, 2012
- Asahi Kasei Pharma Launches Flivas in South Korea through Dong-A
January 10, 2012
- Pharmacist Survey Shows Meiji Seika Pharma Rise to 3rd Rank for “Memorable” MRs
January 6, 2012
- Deutsche Securities Report Says Patent Cliff Concerns Scarce for MTPC
January 6, 2012
- AZ President Hudson Says Development of Japanese Leaders One of Key Company Issues
January 6, 2012
- AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
- Top Execs Stress Importance of Emerging Markets, Compliance in New Year's Addresses
January 6, 2012
- Toray to Take Equity Stake in Mitsui’s Subsidiary
January 6, 2012
- Seikagaku Changes Sales Partner for Supartz in US
January 6, 2012
- Astellas Directed to Suspend Export of Gaster to South Korea Due to Use of Unapproved API
January 6, 2012
- Meiji Seika Pharma Submits Application for ME2080 to Treat Dravet’s Syndrome
January 6, 2012
- Tivozanib Significantly Improves PFS Compared to Sorafenib in RCC: Astellas
January 6, 2012
- Takara Bio, Mie Univ. to Collaborate in Clinical Trial of Cancer Treatment
January 6, 2012
- RaQualia Licenses COX-2 Inhibitor in China
January 5, 2012
- Takeda Voluntarily Recalls Bestcall IM Inj. 0.5 g
January 5, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…